ZA200808420B - Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides - Google Patents

Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides

Info

Publication number
ZA200808420B
ZA200808420B ZA200808420A ZA200808420A ZA200808420B ZA 200808420 B ZA200808420 B ZA 200808420B ZA 200808420 A ZA200808420 A ZA 200808420A ZA 200808420 A ZA200808420 A ZA 200808420A ZA 200808420 B ZA200808420 B ZA 200808420B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
mirna
sense oligonucleotides
oligonucleotides
sense
Prior art date
Application number
ZA200808420A
Inventor
Elmen Joacim
Kearney Phil
Kauppinen Sakari
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Publication of ZA200808420B publication Critical patent/ZA200808420B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
ZA200808420A 2006-04-03 2008-10-02 Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides ZA200808420B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200600478 2006-04-03

Publications (1)

Publication Number Publication Date
ZA200808420B true ZA200808420B (en) 2009-08-26

Family

ID=36746645

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808420A ZA200808420B (en) 2006-04-03 2008-10-02 Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides

Country Status (3)

Country Link
CN (1) CN101437942A (en)
NZ (1) NZ594605A (en)
ZA (1) ZA200808420B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102311956B (en) * 2011-09-20 2012-11-21 浙江大学 Specific base modification antisense nucleotide chain and application thereof
CN105087477A (en) * 2015-05-21 2015-11-25 王松灵 Application of mesenchymal stem cell modified by miR-21 antisense nucleotide
WO2016196978A1 (en) * 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)
WO2016197024A2 (en) * 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
CA2997786A1 (en) * 2015-09-22 2017-03-30 MiRagen Therapeutics, Inc. Mir-19 modulators and uses thereof
WO2017132945A1 (en) * 2016-02-04 2017-08-10 中国科学技术大学 Design and application of mirancer molecule
CN112585280A (en) * 2018-08-23 2021-03-30 罗氏创新中心哥本哈根有限公司 Micro RNA-134 biomarkers

Also Published As

Publication number Publication date
CN101437942A (en) 2009-05-20
NZ594605A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
IL194007A0 (en) Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
SG10201406016SA (en) Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
IL198911A0 (en) Drug delivery
HK1125295A1 (en) Microtablet-based pharmaceutical preparation
EP2001498A4 (en) Pharmaceutical compositions
IL194176A0 (en) Pharmaceutical compositions
HUE063083T2 (en) Pharmaceutical compositions comprising nilotinib
GB0713625D0 (en) Pharmaceutical compositions
ZA200901175B (en) Drug dispenser
HK1138732A1 (en) Pharmaceutical compositions
GB0614586D0 (en) Pharmaceutical Formulation
EP2010162A4 (en) Drug delivery composition
ZA200901093B (en) Drug dispenser
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
ZA200808420B (en) Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides
GB0625783D0 (en) Medicament
GB0614365D0 (en) Pharmaceutical compositions and their use
EP2124959A4 (en) Pharmaceutical composition
IL198160A0 (en) Pharmaceutical formulations
GB0615064D0 (en) Medicament
HU0600097D0 (en) Pharmaceutical composition comprising tacrolimus
EP2197454A4 (en) Pharmaceutical compositions for administering oligonucleotides
GB0615814D0 (en) Medicament
ZA200708369B (en) Medicament
GB0623402D0 (en) Medicament dispenser